Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
EOLS vs AVAH vs ABBV vs PNTG vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Drug Manufacturers - General
Medical - Care Facilities
Medical - Distribution
EOLS vs AVAH vs ABBV vs PNTG vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Care Facilities | Drug Manufacturers - General | Medical - Care Facilities | Medical - Distribution |
| Market Cap | $421M | $1.46B | $358.42B | $1.24B | $92.15B |
| Revenue (TTM) | $301M | $2.43B | $61.16B | $1.02B | $403.43B |
| Net Income (TTM) | $-43M | $225M | $4.23B | $30M | $4.76B |
| Gross Margin | 65.7% | 33.1% | 70.2% | 11.1% | 3.6% |
| Operating Margin | -9.6% | 10.9% | 26.7% | 5.6% | 1.5% |
| Forward P/E | — | 12.0x | 14.3x | 27.0x | 19.3x |
| Total Debt | $155M | $1.34B | $69.07B | $453M | $7.39B |
| Cash & Equiv. | $54M | $193M | $5.23B | $17M | $5.69B |
EOLS vs AVAH vs ABBV vs PNTG vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 100 | 70.1 | -29.9% |
| Aveanna Healthcare … (AVAH) | 100 | 59.4 | -40.6% |
| AbbVie Inc. (ABBV) | 100 | 181.7 | +81.7% |
| The Pennant Group, … (PNTG) | 100 | 88.4 | -11.6% |
| McKesson Corporation (MCK) | 100 | 401.1 | +301.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EOLS vs AVAH vs ABBV vs PNTG vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, EOLS doesn't own a clear edge in any measured category.
AVAH carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (12.0x vs 27.0x)
- 9.2% margin vs EOLS's -14.4%
- +44.0% vs EOLS's -45.7%
- 12.4% ROA vs EOLS's -19.4%, ROIC 15.1% vs -44.5%
ABBV is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 13 yrs, beta 0.34, yield 3.2%
- Beta 0.34, yield 3.2%, current ratio 0.67x
- 3.2% yield, 13-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
PNTG ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 36.3%, EPS growth 18.3%, 3Y rev CAGR 26.0%
- Lower volatility, beta 0.79, current ratio 1.14x
- 36.3% revenue growth vs ABBV's 8.6%
MCK is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 348.1% 10Y total return vs ABBV's 295.5%
- PEG 0.49 vs PNTG's 2.68
- Beta 0.04 vs AVAH's 1.40
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.3% revenue growth vs ABBV's 8.6% | |
| Value | Lower P/E (12.0x vs 27.0x) | |
| Quality / Margins | 9.2% margin vs EOLS's -14.4% | |
| Stability / Safety | Beta 0.04 vs AVAH's 1.40 | |
| Dividends | 3.2% yield, 13-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +44.0% vs EOLS's -45.7% | |
| Efficiency (ROA) | 12.4% ROA vs EOLS's -19.4%, ROIC 15.1% vs -44.5% |
EOLS vs AVAH vs ABBV vs PNTG vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EOLS vs AVAH vs ABBV vs PNTG vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AVAH leads in 2 of 6 categories
ABBV leads 1 • MCK leads 1 • EOLS leads 0 • PNTG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ABBV leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 1338.5x EOLS's $301M. AVAH is the more profitable business, keeping 9.2% of every revenue dollar as net income compared to EOLS's -14.4%. On growth, PNTG holds the edge at +36.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $301M | $2.4B | $61.2B | $1.0B | $403.4B |
| EBITDAEarnings before interest/tax | -$21M | $289M | $24.5B | $66M | $6.8B |
| Net IncomeAfter-tax profit | -$43M | $225M | $4.2B | $30M | $4.8B |
| Free Cash FlowCash after capex | -$41M | $126M | $18.7B | $47M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +65.7% | +33.1% | +70.2% | +11.1% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -9.6% | +10.9% | +26.7% | +5.6% | +1.5% |
| Net MarginNet income ÷ Revenue | -14.4% | +9.2% | +6.9% | +3.0% | +1.2% |
| FCF MarginFCF ÷ Revenue | -13.7% | +5.2% | +30.6% | +4.6% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | +27.4% | +10.0% | +36.0% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.7% | +4.9% | +57.4% | +9.1% | +37.0% |
Valuation Metrics
AVAH leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 6.6x trailing earnings, AVAH trades at a 92% valuation discount to ABBV's 85.5x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs PNTG's 4.23x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $421M | $1.5B | $358.4B | $1.2B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $522M | $2.6B | $422.3B | $1.7B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | 6.61x | 85.50x | 42.54x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.96x | 14.28x | 26.97x | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 4.23x | 0.75x |
| EV / EBITDAEnterprise value multiple | — | 9.04x | 14.96x | 27.97x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 1.42x | 0.60x | 5.86x | 1.31x | 0.26x |
| Price / BookPrice ÷ Book value/share | — | 7.67x | — | 3.37x | — |
| Price / FCFMarket cap ÷ FCF | — | 11.63x | 20.12x | 47.16x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $8 for PNTG. PNTG carries lower financial leverage with a 1.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to AVAH's 6.91x. On the Piotroski fundamental quality scale (0–9), AVAH scores 6/9 vs PNTG's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +9.5% | +62.1% | +8.4% | +3.0% |
| ROA (TTM)Return on assets | -19.4% | +12.4% | +3.1% | +3.5% | +5.7% |
| ROICReturn on invested capital | -44.5% | +15.1% | +23.9% | +5.6% | +5.4% |
| ROCEReturn on capital employed | -23.5% | +18.6% | +21.5% | +7.3% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 6.91x | — | 1.21x | — |
| Net DebtTotal debt minus cash | $101M | $1.2B | $63.8B | $436M | $1.7B |
| Cash & Equiv.Liquid assets | $54M | $193M | $5.2B | $17M | $5.7B |
| Total DebtShort + long-term debt | $155M | $1.3B | $69.1B | $453M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -1.92x | 1.79x | 3.28x | 16.52x | 33.79x |
Total Returns (Dividends Reinvested)
AVAH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $6,019 for AVAH. Over the past 12 months, AVAH leads with a +44.0% total return vs EOLS's -45.7%. The 3-year compound annual growth rate (CAGR) favors AVAH at 89.5% vs EOLS's -10.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.9% | -14.1% | -10.1% | +28.4% | -8.5% |
| 1-Year ReturnPast 12 months | -45.7% | +44.0% | +11.3% | +28.7% | +4.6% |
| 3-Year ReturnCumulative with dividends | -28.4% | +580.4% | +50.4% | +204.1% | +106.4% |
| 5-Year ReturnCumulative with dividends | -30.1% | -39.8% | +101.3% | -6.9% | +286.9% |
| 10-Year ReturnCumulative with dividends | -44.4% | -42.2% | +295.5% | +136.8% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -10.6% | +89.5% | +14.6% | +44.9% | +27.3% |
Risk & Volatility
Evenly matched — PNTG and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than AVAH's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PNTG currently trades 99.7% from its 52-week high vs EOLS's 52.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.40x | 0.34x | 0.79x | 0.04x |
| 52-Week HighHighest price in past year | $12.16 | $10.32 | $244.81 | $35.84 | $999.00 |
| 52-Week LowLowest price in past year | $3.86 | $3.73 | $176.57 | $21.73 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +52.5% | +67.2% | +82.8% | +99.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 76.1 | 53.4 | 46.8 | 62.5 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.1M | 5.8M | 245K | 757K |
Analyst Outlook
Evenly matched — ABBV and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EOLS as "Buy", AVAH as "Hold", ABBV as "Buy", PNTG as "Buy", MCK as "Buy". Consensus price targets imply 134.7% upside for EOLS (target: $15) vs 9.2% for PNTG (target: $39). For income investors, ABBV offers the higher dividend yield at 3.24% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $11.00 | $256.64 | $39.00 | $1006.50 |
| # AnalystsCovering analysts | 13 | 12 | 41 | 7 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.2% | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | — | 13 | 1 | 17 |
| Dividend / ShareAnnual DPS | — | — | $6.57 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.3% | 0.0% | +3.4% |
AVAH leads in 2 of 6 categories (Valuation Metrics, Total Returns). ABBV leads in 1 (Income & Cash Flow). 2 tied.
EOLS vs AVAH vs ABBV vs PNTG vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EOLS or AVAH or ABBV or PNTG or MCK a better buy right now?
For growth investors, The Pennant Group, Inc.
(PNTG) is the stronger pick with 36. 3% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Aveanna Healthcare Holdings Inc. (AVAH) offers the better valuation at 6. 6x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EOLS or AVAH or ABBV or PNTG or MCK?
On trailing P/E, Aveanna Healthcare Holdings Inc.
(AVAH) is the cheapest at 6. 6x versus AbbVie Inc. at 85. 5x. On forward P/E, Aveanna Healthcare Holdings Inc. is actually cheaper at 12. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus The Pennant Group, Inc. 's 2. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — EOLS or AVAH or ABBV or PNTG or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -39. 8% for Aveanna Healthcare Holdings Inc. (AVAH). Over 10 years, the gap is even starker: MCK returned +348. 1% versus EOLS's -44. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EOLS or AVAH or ABBV or PNTG or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Aveanna Healthcare Holdings Inc. 's 1. 40β — meaning AVAH is approximately 3152% more volatile than MCK relative to the S&P 500. On balance sheet safety, The Pennant Group, Inc. (PNTG) carries a lower debt/equity ratio of 121% versus 7% for Aveanna Healthcare Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EOLS or AVAH or ABBV or PNTG or MCK?
By revenue growth (latest reported year), The Pennant Group, Inc.
(PNTG) is pulling ahead at 36. 3% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Aveanna Healthcare Holdings Inc. grew EPS 1952% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, PNTG leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EOLS or AVAH or ABBV or PNTG or MCK?
Aveanna Healthcare Holdings Inc.
(AVAH) is the more profitable company, earning 9. 2% net margin versus -17. 4% for Evolus, Inc. — meaning it keeps 9. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -12. 7% for EOLS. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EOLS or AVAH or ABBV or PNTG or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus The Pennant Group, Inc. 's 2. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Aveanna Healthcare Holdings Inc. (AVAH) trades at 12. 0x forward P/E versus 27. 0x for The Pennant Group, Inc. — 15. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EOLS: 134. 7% to $15. 00.
08Which pays a better dividend — EOLS or AVAH or ABBV or PNTG or MCK?
In this comparison, ABBV (3.
2% yield), MCK (0. 4% yield) pay a dividend. EOLS, AVAH, PNTG do not pay a meaningful dividend and should not be held primarily for income.
09Is EOLS or AVAH or ABBV or PNTG or MCK better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc.
(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, AVAH: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EOLS and AVAH and ABBV and PNTG and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EOLS is a small-cap quality compounder stock; AVAH is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; PNTG is a small-cap high-growth stock; MCK is a mid-cap high-growth stock. ABBV pays a dividend while EOLS, AVAH, PNTG, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.